Tech Company Financing Transactions
BioVex Funding Round
Harris & Harris Group, Oxford Finance and Silicon Valley Bank invested in a $13 million Series E funding round for BioVex. The round was announced on 11/15/2007.
Transaction Overview
Company Name
Announced On
11/15/2007
Transaction Type
Debt
Venture Equity
Venture Equity
Amount
$13,000,000
Round
Series E
Proceeds Purpose
BioVex intends to use the capital to complete its preparations for, and to commence, a Phase III study with its lead product OncoVexGM-CSF for the treatment of melanoma as well as to complete studies in head and neck cancer and pancreatic cancer. The financing will also fund the Company's second program, ImmunoVEXHSV2, a vaccine for genital herpes, through to Phase II.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
34 Commerce Way
Woburn, MA 01801
USA
Woburn, MA 01801
USA
Phone
Website
Email Address
Overview
The Company is developing a new class of potent biologics for the treatmentof cancer and prevention of infectious disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Philip Astley-Sparke
Chief Financial Officer
Stephen Gorgol
Chief Medical Officer
Howard Goldsweig
Chief Technical Officer
Robert Coffin
VP - Bus. Development
Pamela Esposito
VP - Manufacturing
Paul Bullock
VP - Operations
Timothy Hanke
VP - Operations
Lance Weed
VP - Product Management
Colin Love
VP - Regulatory Affairs
Anne Woodland
Browse more venture capital transactions:
Prev: 11/15/2007: Apptio venture capital transaction
Next: 11/15/2007: Symbios Medical Products venture capital transaction
Share this article
About Our Venture Capital Transactions Database
Our team works diligently to record every notable VC transaction. All VC database entries reported here are sourced from publicly available VC deal announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs